Literature DB >> 8770511

Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.

E Grimprel1, P Bégué, I Anjak, E Njamkepo, P François, N Guiso.   

Abstract

Three hundred sixty children were tested for pertussis serology 0.5 to 1.58 months after complete whole-cell pertussis vaccination. An immunoblot assay was used to detect serum antibodies to pertussis toxin, filamentous hemagglutinin, adenylate cyclase-hemolysin, and pertactin, and agglutination was used for detection of anti-agglutinogen antibodies. Antibodies against pertussis toxin, pertactin, and agglutinogens decreased rapidly after vaccination but increased secondarily, suggesting exposure to infected persons. In contrast, anti-filamentous hemagglutinin antibodies persisted and anti-adenylate cyclase-hemolysin antibodies increased continuously, suggesting either cross-reaction with non-Bordetella antigens or exposure to Bordetella isolates expressing these two antigens, including Bordetella pertussis. These data suggest that unrecognized pertussis is common in France despite massive and sustained immunization in infants and that vaccinated children become susceptible to infection more than 6 years after their last vaccination.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770511      PMCID: PMC170254          DOI: 10.1128/cdli.3.1.93-97.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection.

Authors:  N Khelef; H Sakamoto; N Guiso
Journal:  Microb Pathog       Date:  1992-03       Impact factor: 3.738

2.  Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.

Authors:  E Relyveld; N H Oato; N Guérin; P Coursaget; M Huet; R K Gupta
Journal:  Vaccine       Date:  1991-11       Impact factor: 3.641

3.  Natural history of pertussis antibody in the infant and effect on vaccine response.

Authors:  J Van Savage; M D Decker; K M Edwards; S H Sell; D T Karzon
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

4.  Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin.

Authors:  N Khelef; A Zychlinsky; N Guiso
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

5.  Unrecognized pertussis infection in adolescents.

Authors:  B A Cromer; J Goydos; J Hackell; J Mezzatesta; C Dekker; E A Mortimer
Journal:  Am J Dis Child       Date:  1993-05

6.  Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine.

Authors:  M E Ramsay; M Rao; N T Begg; K Redhead; A M Attwell
Journal:  Lancet       Date:  1993-07-24       Impact factor: 79.321

Review 7.  Human infections associated with Bordetella bronchiseptica.

Authors:  B F Woolfrey; J A Moody
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

8.  Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization.

Authors:  N Guiso; M Szatanik; M Rocancourt
Journal:  Microb Pathog       Date:  1991-12       Impact factor: 3.738

9.  Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination.

Authors:  Z Farfel; S Könen; E Wiertz; R Klapmuts; P A Addy; E Hanski
Journal:  J Med Microbiol       Date:  1990-07       Impact factor: 2.472

10.  Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families.

Authors:  C Locht; M C Geoffroy; G Renauld
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  16 in total

1.  Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.

Authors:  C Weber; C Boursaux-Eude; G Coralie; V Caro; N Guiso
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Pertussis is increasing in unimmunized infants: is a change in policy needed?

Authors:  S Ranganathan; R Tasker; R Booy; P Habibi; S Nadel; J Britto
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

Review 3.  Laboratory diagnosis of pertussis: state of the art in 1997.

Authors:  F M Müller; J E Hoppe; C H Wirsing von König
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

Review 4.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

Review 5.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Use of a Toxin Neutralization Assay To Characterize the Serologic Response to Adenylate Cyclase Toxin after Infection with Bordetella pertussis.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Tod J Merkel; Erik L Hewlett
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

7.  Comparison of commercially available immunoblot assays measuring IgG and IgA antibodies to Bordetella pertussis antigens.

Authors:  N Kennerknecht; M Riffelmann; J Schmetz; C H Wirsing von König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-20       Impact factor: 3.267

Review 8.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 9.  Protecting Newborns Against Pertussis: Treatment and Prevention Strategies.

Authors:  Abdulbaset M Salim; Yan Liang; Paul E Kilgore
Journal:  Paediatr Drugs       Date:  2015-12       Impact factor: 3.022

10.  Whole-cell pertussis vaccine induces low antibody levels in human immunodeficiency virus-infected children living in sub-Saharan Africa.

Authors:  Mathurin C Tejiokem; Elisabeth Njamkepo; Ionela Gouandjika; Dominique Rousset; Lydie Béniguel; Catherine Bilong; Gilbert Tene; Ida Penda; Carine Ngongueu; Jean C Gody; Nicole Guiso; Laurence Baril
Journal:  Clin Vaccine Immunol       Date:  2009-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.